Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed diagnosis of carcinoma~* Stage II-III (T2, T3, N0 or T1-3, N1) carcinoma of head and neck, including: oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus~* No N2 or N3~* Measurable disease is not required~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-3~Life expectancy:~* Anticipated survival is 3-4 years (median)~Hematopoietic:~* WBC count at least 3.5/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* Not specified~Pulmonary:~* Not specified~Other:~* No infection or severe medical illness~* Not pregnant~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* No prior surgery

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Hyper-FHX) (Type: EXPERIMENTAL): Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).